Regulation & law · 30/08/2011Updated: 10/17/2026 · 1 min read
U.S. District Court Approves Pfizer's Acquisition of BioNTech, Following Review of Proposed Transaction
Summary
The U.S. District Court for the Southern District of New York has approved Pfizer's acquisition of BioNTech, following a review of the proposed transaction, which was announced in January 2023 and valued at $68 billion, according to reports.
Original source language: Federal Register — Justice DepartmentOpen original release →